title: Long-term remission of lymphocytic hypereosinophilic syndrome with imatinib mesylate.
authors.forename: Anna
authors.initials: A
authors.lastname: Christoforidou
authors.forename: Ioannis
authors.initials: I
authors.lastname: Kotsianidis
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Margaritis
authors.forename: Athanasios
authors.initials: A
authors.lastname: Anastasiadis
authors.forename: Eudoxia
authors.initials: E
authors.lastname: Douvali
authors.forename: Costas
authors.initials: C
authors.lastname: Tsatalas
mesh_terms: D000368:Aged; D001549:Benzamides; D001854:Bone Marrow Cells / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy* / Q000378:metabolism; D000068877:Imatinib Mesylate; D008214:Lymphocytes / Q000378:metabolism; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000378:metabolism; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D016693:Receptors, Antigen, T-Cell, alpha-beta; D000068877:Imatinib Mesylate